Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
The Barrick Mining Corporation (NYSE: B, TSX: ABX) news page on Stock Titan provides a focused view of company announcements and market-facing disclosures for one of the world’s largest gold miners. Barrick’s news flow reflects its role as a major producer of gold and copper, with operations and projects across the Americas, Africa, the Middle East, and Asia.
Investors following B stock can use this page to track key corporate updates that shape the company’s outlook. These include notices about upcoming earnings releases and webcasts, such as the announcement that Barrick will report its full year and fourth quarter 2025 results on February 5, 2026, with a live webcast and analyst question-and-answer session. Such events offer insight into production performance, costs, project progress, and capital allocation decisions.
Alongside earnings-related news, Barrick’s regulatory communications often appear in the form of press releases furnished with its Form 6-K filings. These may cover quarterly results, comparative unaudited financial statements prepared in accordance with International Financial Reporting Standards, management’s discussion and analysis, and capital management actions such as share buyback programs.
By reviewing the Barrick Mining Corporation news feed, readers can monitor how the company reports on its gold and copper production profile, reserve base, and key projects like the Lumwana expansion and the Reko Diq copper and gold development. Bookmark this page to quickly access the latest Barrick announcements, scheduled results dates, and other official disclosures that inform analysis of the B stock.
BioArctic (NASDAQ Stockholm: B) will publish its fourth quarter report for October–December 2025 on 18 February 2026 at 08:00 a.m. CET. A presentation with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 09:30 a.m. CET, including a Q&A, webcast and teleconference options.
Registration links, dial-in information, and archived webcast access are provided on the company's investor site. Contact details for investor relations are listed for follow-up.
BioArctic (NASDAQ: B) reports that Leqembi global sales were JPY 20.7 billion in Q4 2025, generating a royalty to BioArctic of SEK 127 million. This royalty rose ~31% versus Q4 2024; at constant exchange rates the SEK increase would be ~50%, reflecting currency effects.
Eisai will publish its Q3 FY2025 results on February 9, 2026 and BioArctic will publish its FY2025 report on February 18, 2026 at 08:00 CET.
Barrick (NYSE:B) reported record quarterly results for Q4 2025 with $6.00 billion revenue, operating cash flow of $2.73 billion and free cash flow of $1.62 billion. Full-year 2025 revenue was $16.96 billion, net earnings per share $2.93, and gold production 3.26 million oz.
The Board approved a new dividend framework targeting 50% of attributable free cash flow, a quarterly base dividend increase to $0.175 and declared $0.42 per share for Q4. Management will prepare an IPO of North American gold assets (NewCo), targeting completion by late 2026.
Barrick (NYSE:B) declared a $0.42 per share dividend for Q4 2025, a 140% increase versus Q3, payable March 16, 2026 to holders of record February 27, 2026. The company also announced a new dividend policy targeting a 50% annual payout of attributable free cash flow.
Barrick repurchased ~12.11 million shares in Q4 and ~51.90 million shares in 2025 (~3.0% of shares) for $1.5 billion cash, including $500 million in Q4. The new policy sets a fixed quarterly base dividend of $0.175 per share plus a year-end performance top-up.
Barrick (NYSE:B) appointed Robert Samek to its Board of Directors and named Mark Hill President and CEO, elevating him to the Board as a Non-Independent Director on Feb 5, 2026. Samek will join the Audit & Risk and Compensation committees and brings 31 years at McKinsey with leadership in mining, AI for energy and capital projects.
The Board cited Hill’s strong operational performance and said his board role will support the planned IPO process for Barrick’s North American gold assets.
Cereno Scientific (NASDAQ First North: B) is broadening the development focus of its orally administered HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company completed a Phase I study and plans a Phase II program aimed to start in Q1 2027. The shift intends to target a patient population with high unmet need and align CS014 with combined fibrotic and pulmonary vascular pathology to strengthen clinical and strategic positioning.
Crawford & Company (NYSE:A) announced a new global operating structure effective January 1, 2026, consolidating into two divisions: U.S. Operations and International Operations.
Mike Hoberman was promoted to CEO, U.S. Operations, reporting to interim President & CEO Bruce Swain. Canada will transition into International Operations under Andrew Bart. Pat Van Bakel was named chief commercial & strategy officer. New U.S. presidents named: Paul Kottler, Lance Malcolm and Jeffrey Sickles.
Barrick (NYSE:B) announced that Helen Cai will become Senior Executive Vice President and Chief Financial Officer effective March 1, 2026, following the departure of Graham Shuttleworth after the company’s year-end results. Ms. Cai will work with Mr. Shuttleworth during a transition period. Ms. Cai has served on Barrick’s board since November 2021 and brings over two decades of finance and mining‑sector experience, CFA and CAIA designations, and prior roles at Goldman Sachs and CICC.
Cereno Scientific (NASDAQ First North: B) announced a peer-reviewed publication (Journal of Thrombosis and Haemostasis) on CS014, a novel HDAC inhibitor engineered to improve upon valproic acid by reducing hepatotoxic 4-ene metabolite formation while preserving HDAC activity. The manuscript reports potent antithrombotic effects across small artery, large artery and large vein models achieved at doses that preserve normal coagulation and bleeding time. Cereno also reported positive Phase I safety and tolerability at exposures predicted to support efficacy and said it is preparing for Phase II with initial focus on idiopathic pulmonary fibrosis.
Hexagon US Federal (B) announced leadership transitions to support operational execution and mission delivery. On January 2, 2026, Elliott Ferguson was appointed President after serving as VP of Geospatial Solutions and being named Chief Operating Officer in 2024; Ferguson will focus on strategic execution, customer delivery and long-term growth. The company also named Phil Chandler VP of Business Operations, Victoria Privett VP of Corporate Services, Greta Brant Director of Contracts and Marc Langlois Director of Sales.
The appointments aim to position Hexagon US Federal to continue delivering solutions amid a potential Octave spinoff from Hexagon AB slated for the first half of 2026, with Octave focused on software, SaaS, analytics and AI-driven offerings.